Overview

Low-dose IL-2( Interleukin-2) Treatment in SLE

Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This clinical study will test the efficacy and safety of low dose IL-2 treatment in Systemic lupus erythematosus.
Phase:
N/A
Details
Lead Sponsor:
Peking University People's Hospital
Collaborator:
Monash University
Treatments:
Interleukin-2